CONTACT INFORMATION
| Phone: (216) 368-4370 |
| Fax: (216) 368-4223 |
| Email: pamela.davis@case.edu |
Office: BRB 8th floor, 2109 Adelbert Rd, Cleveland, OH 44106
|
EDUCATION
|
M.D., Duke University
Ph.D., Duke University (Physiology and Pharmacology)
B.A. Smith College |
ACTIVE RESEARCH
Developing DNA nanoparticles for gene therapy. Primary target is the lung in cystic fibrosis with delivery of the CF gene, but secondary targets include prevention of influenza with DNA encoding shRNAs, and other target organs.
Investigating the manner in which defects in CFTR lead to excess inflammation in response to infection in the CF lung, and discovering ways to correct it. |
 |
POTENTIAL IMPACT
SELECTED PUBLICATIONS
Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Ziady AG, Moen RC, Cooper MJ. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther. 2004 Dec;15(12):1255-69.
Ziady AG, Kim J, Colla J, Davis PB. Defining strategies to extend duration of gene expression from targeted compacted DNA vectors. Gene Ther. 2004 Sep;11(18):1378-90.
Ziady AG, Gedeon CR, Muhammad O, Stillwell V, Oette SM, Fink TL, Quan W, Kowalczyk TH, Hyatt SL, Payne J, Peischl A, Seng JE, Moen RC, Cooper MJ, Davis PB. Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther. 2003 Dec;8(6):948-56.
Ziady AG, Gedeon CR, Muhammad O, Stillwell V, Oette SM, Fink TL, Quan W, Kowalczyk TH, Hyatt SL, Payne J, Peischl A, Seng JE, Moen RC, Cooper MJ, Davis PB. Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther. 2003 Dec;8(6):948-56.
FIELDS
|
